Syndecan-2-positive, bone marrow-derived human mesenchymal stromal cells attenuate bacterial-induced acute lung injury and enhance resolution of ventilator-induced lung injury in rats

Anesthesiology

Volumn 129, Issue 3, 2018, Pages 502-516

  Masterson, Claire ^a   Devaney, James ^a   Horie, Shahd ^a   O'Flynn, Lisa ^b   Deedigan, Laura ^b   Elliman, Steve ^b   Barry, Frank ^a   O'Brien, Timothy ^a,c   O'Toole, Daniel ^a   Laffey, John G ^a,c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b Orbsen Therapeutics Ltd   (Ireland)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNDECAN 2; SDC2 PROTEIN, HUMAN;

ACUTE LUNG INJURY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL OXYGEN SATURATION; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG COMPLIANCE; MACROPHAGE; MALE; MESENCHYMAL STROMA CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; VENTILATOR INDUCED LUNG INJURY; WOUND CLOSURE; A-549 CELL LINE; ANIMAL; BIOSYNTHESIS; BONE MARROW; ESCHERICHIA COLI INFECTION; ISOLATION AND PURIFICATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; MICROBIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; U-937 CELL LINE;

A549 CELLS; ACUTE LUNG INJURY; ANIMALS; BONE MARROW; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; RATS; RATS, SPRAGUE-DAWLEY; SYNDECAN-2; U937 CELLS; VENTILATOR-INDUCED LUNG INJURY;

EID: 85056575731     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000002327     Document Type: Article

References (43)

1. Gotts JE, Matthay MA: Mesenchymal stem cells and acute lung injury. Crit Care Clin 2011; 27: 719-33
2. Mao M, Wang SN, Lv XJ, Wang Y, Xu JC: Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats. Shock 2010; 34: 196-204
3. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesen-chymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179: 1855-63
4. Ionescu L, Byrne RN, van Haaften T, Vadivel A, Alphonse RS, Rey-Parra GJ, Weissmann G, Hall A, Eaton F, Thébaud B: Stem cell conditioned medium improves acute lung injury in mice: In vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol 2012; 303: L967-77
5. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrini M, Matthay MA: Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; 302: L1003-13
6. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182: 1047-57
7. Nemeth K, Mayer B, Mezey E: Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J Mol Med (Berl) 2010; 88: 5-10
8. Chimenti L, Luque T, Bonsignore MR, Ramírez J, Navajas D, Farré R: Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury. Eur Respir J 2012; 40: 939-48
9. Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, Laurent G, Bonnet D, Janes SM: Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009; 4: e8013
10. Ortiz L, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney D: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 8407-11
11. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, Fine A: Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001; 128: 5181-8
12. Curley GF, Hayes M, Ansari B, Shaw G, Ryan A, Barry F, O'Brien T, O'Toole D, Laffey JG: Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax 2012; 67: 496-501
13. Curley GF, Ansari B, Hayes M, Devaney J, Masterson C, Ryan A, Barry F, O'Brien T, Toole DO, Laffey JG: Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. ANESTHESIOLOGY 2013; 118: 924-32
14. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA: Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187: 751-60
15. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA: Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28: 2229-38
16. Asmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, McAuley DF, McKenna DH, Traber LD, Zhuo H, Wilson J, Herndon DN, Prough DS, Liu KD, Matthay MA, Enkhbaatar P: Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 2014; 69: 819-25
17. Devaney J, Horie S, Masterson C, Elliman S, Barry F, O'Brien T, Curley GF, O'Toole D, Laffey JG: Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 2015; 70: 625-35
18. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, Matthay MA: Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012; 67: 533-9
19. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA: Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187: 751-60
20. Hayes M, Curley GF, Masterson C, Devaney J, O'Toole D, Laffey JG: Mesenchymal stromal cells are more effective than the MSC secretome in diminishing injury and enhancing recovery following ventilator-induced lung injury. Intensive Care Med Exp 2015; 3: 29
21. Hayes M, Masterson C, Devaney J, Barry F, Elliman S, O'Brien T, O'Toole D, Curley GF, Laffey JG: Therapeutic efficacy of human mesenchymal stromal cells in the repair of established ventilator-induced lung injury in the rat. ANESTHESIOLOGY 2015; 122: 363-73
22. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA: Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med 2015; 3: 24-32
23. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7
24. Phinney DG: Biochemical heterogeneity of mesenchymal stem cell populations: Clues to their therapeutic efficacy. Cell Cycle 2007; 6: 2884-9
25. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788-800
26. Laffey JG, Kavanagh BP: Fifty years of research in ARDS. Insight into acute respiratory distress syndrome. From models to patients. Am J Respir Crit Care Med 2017; 196: 18-28
27. Markowicz P, Wolff M, Djedaïni K, Cohen Y, Chastre J, Delclaux C, Merrer J, Herman B, Veber B, Fontaine A, Dreyfuss D: Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk factors. ARDS Study Group. Am J Respir Crit Care Med 2000; 161: 1942-8
28. Zilberberg MD, Epstein SK: Acute lung injury in the medical ICU: Comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 1998; 157(4 Pt 1):1159-64
29. TenHoor T, Mannino DM, Moss M: Risk factors for ARDS in the United States: Analysis of the 1993 National Mortality Followback Study. Chest 2001; 119: 1179-84
30. Cabrera-Benitez NE, Laffey JG, Parotto M, Spieth PM, Villar J, Zhang H, Slutsky AS: Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: A significant contributor to poor outcome. ANESTHESIOLOGY 2014; 121: 189-98
31. O'Toole D, Hassett P, Contreras M, Higgins BD, McKeown ST, McAuley DF, O'Brien T, Laffey JG: Hypercapnic acidosis attenuates pulmonary epithelial wound repair by an NF-kappaB dependent mechanism. Thorax 2009; 64: 976-82
32. Curley GF, Jerkic M, Dixon S, Hogan G, Masterson C, O'Toole D, Devaney J, Laffey JG: Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent Escherichia coli-induced acute respiratory distress syndrome. Crit Care Med 2017; 45: e202-12
33. Devaney J, Curley GF, Hayes M, Masterson C, Ansari B, O'Brien T, O'Toole D, Laffey JG: Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia. Crit Care 2013; 17: R82
34. O'Croinin DF, Hopkins NO, Moore MM, Boylan JF, McLoughlin P, Laffey JG: Hypercapnic acidosis does not modulate the severity of bacterial pneumonia-induced lung injury. Crit Care Med 2005; 33: 2606-12
35. O'Croinin DF, Nichol AD, Hopkins N, Boylan J, O'Brien S, O'Connor C, Laffey JG, McLoughlin P: Sustained hyper-capnic acidosis during pulmonary infection increases bacterial load and worsens lung injury. Crit Care Med 2008; 36: 2128-35
36. Curley GF, Contreras M, Higgins B, O'Kane C, McAuley DF, O'Toole D, Laffey JG: Evolution of the inflammatory and fibro-proliferative responses during resolution and repair following ventilator-induced lung injury in the rat. ANESTHESIOLOGY 2011; 115: 1022-32
37. Costello J, Higgins B, Contreras M, Chonghaile MN, Hassett P, O'Toole D, Laffey JG: Hypercapnic acidosis attenuates shock and lung injury in early and prolonged systemic sepsis. Crit Care Med 2009; 37: 2412-20
38. Higgins BD, Costello J, Contreras M, Hassett P, O'Toole D, Laffey JG: Differential effects of buffered hypercapnia versus hypercapnic acidosis on shock and lung injury induced by systemic sepsis. ANESTHESIOLOGY 2009; 111: 1317-26
39. Laffey JG, Honan D, Hopkins N, Hyvelin JM, Boylan JF, McLoughlin P: Hypercapnic acidosis attenuates endotoxin-induced acute lung injury. Am J Respir Crit Care Med 2004; 169: 46-56
40. Phinney DG: Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy. J Cell Biochem 2012; 113: 2806-12
41. Mareddy S, Broadbent J, Crawford R, Xiao Y: Proteomic profiling of distinct clonal populations of bone marrow mesenchymal stem cells. J Cell Biochem 2009; 106: 776-86
42. Rovira-Clavé X, Angulo-Ibáñez M, Reina M, Espel E: The PDZ-binding domain of syndecan-2 inhibits LFA-1 high-affinity conformation. Cell Signal 2014; 26: 1489-99
43. Mukhopadhyay A, Wong MY, Chan SY, Do DV, Khoo A, Ong CT, Cheong HH, Lim IJ, Phan TT: Syndecan-2 and decorin: Proteoglycans with a difference-implications in keloid pathogenesis. J Trauma 2010; 68: 999-1008